Purchase this article with an account.
Abbot F. Clark, Jessamee Mellon, Xiao–Yan Li, Ding Ma, Henry Leher, Rajendra Apte, Hassan Alizadeh, Sushma Hegde, Amanda McLenaghan, Elizabeth Mayhew, Thomas J. D’Orazio, Jerry Y. Niederkorn; Inhibition of Intraocular Tumor Growth by Topical Application of the Angiostatic Steroid Anecortave Acetate. Invest. Ophthalmol. Vis. Sci. 1999;40(9):2158-2162.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. This study examined the effect of an angiostatic agent on the growth of a highly
vascularized intraocular tumor.
methods. A murine uveal melanoma cell line (99E1) was transplanted
intracamerally into athymic nude BALB/c mice. Mice were treated
topically three times per day beginning on the day of tumor
transplantation and continuing through day 28. Groups included (a) 1%
anecortave acetate, (b) vehicle control, or (c) no treatment. Tumor
growth was scored clinically according to the volume of anterior
chamber occupied by tumor. Intraocular tumor weights were determined on
days 10, 14, 21, and 28. The effect of the test agents on tumor cell
proliferation was examined in vitro by [3H]thymidine
results. Tumors grew progressively in untreated mice and mice treated with
the vehicle; tumors filled the entire eye by day 20 and frequently
perforated the globe by day 21. By contrast, tumors treated with
anecortave acetate grew significantly slower (P <
0.025) and did not perforate the eye. On days 21 and 28 the net tumor
weight of the AL-3789–treated animals was 40% to 30% of controls
(P < 0.05). Tumor inhibition was presumably due to
the angiostatic properties of anecortave acetate because the compound
did not affect tumor cell proliferation in vitro.
conclusions. The topical ocular administration of anecortave acetate restricted the
growth of a highly vascularized angiogenic intraocular
This PDF is available to Subscribers Only